JP2021500336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500336A5 JP2021500336A5 JP2020521860A JP2020521860A JP2021500336A5 JP 2021500336 A5 JP2021500336 A5 JP 2021500336A5 JP 2020521860 A JP2020521860 A JP 2020521860A JP 2020521860 A JP2020521860 A JP 2020521860A JP 2021500336 A5 JP2021500336 A5 JP 2021500336A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- dose
- subject
- combination according
- hu5f9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022186496A JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2024003136A JP2024024121A (ja) | 2017-10-18 | 2024-01-12 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574073P | 2017-10-18 | 2017-10-18 | |
| US62/574,073 | 2017-10-18 | ||
| PCT/US2018/056442 WO2019079549A1 (en) | 2017-10-18 | 2018-10-18 | TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022186496A Division JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500336A JP2021500336A (ja) | 2021-01-07 |
| JP2021500336A5 true JP2021500336A5 (https=) | 2021-10-07 |
| JP7308190B2 JP7308190B2 (ja) | 2023-07-13 |
Family
ID=64402251
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521860A Active JP7308190B2 (ja) | 2017-10-18 | 2018-10-18 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2022186496A Active JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2024003136A Withdrawn JP2024024121A (ja) | 2017-10-18 | 2024-01-12 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022186496A Active JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2024003136A Withdrawn JP2024024121A (ja) | 2017-10-18 | 2024-01-12 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210047416A1 (https=) |
| EP (2) | EP4194470A1 (https=) |
| JP (3) | JP7308190B2 (https=) |
| KR (1) | KR20200070341A (https=) |
| CN (1) | CN111315783A (https=) |
| AU (1) | AU2018351007B2 (https=) |
| CA (1) | CA3078430A1 (https=) |
| ES (1) | ES2938652T3 (https=) |
| PL (1) | PL3697819T3 (https=) |
| PT (1) | PT3697819T (https=) |
| SI (1) | SI3697819T1 (https=) |
| WO (1) | WO2019079549A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3747906A1 (en) | 2016-01-11 | 2020-12-09 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| SI4177270T1 (sl) | 2017-10-18 | 2024-10-30 | Forty Seven, Inc. | Terapija za raka jajčnikov na osnovi sredstva proti cd47 |
| AU2019218271B2 (en) | 2018-02-12 | 2024-12-12 | Forty Seven, LLC | Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies |
| US20220289848A1 (en) * | 2019-05-17 | 2022-09-15 | Nanjing GenScript Biotech Co., Ltd. | Anti-cd47/anti-pd-l1 multiple antigen binding proteins and methods of use thereof |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| CN120437288A (zh) * | 2019-12-24 | 2025-08-08 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗卵巢癌的药物组合 |
| TWI855236B (zh) * | 2020-02-28 | 2024-09-11 | 大陸商南京聖和藥業股份有限公司 | 抗cd47/抗pd-l1抗體及其應用 |
| JP7627349B2 (ja) * | 2021-01-08 | 2025-02-05 | 北京韓美薬品有限公司 | 抗ｐｄ－ｌ１／抗ｃｄ４７天然抗体構造様ヘテロダイマー二重特異性抗体及びその製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| PT2970493T (pt) | 2013-03-15 | 2019-06-27 | Univ Leland Stanford Junior | Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47 |
| CN117138060A (zh) * | 2014-10-07 | 2023-12-01 | 免疫医疗公司 | 抗体-药物缀合物的新辅助剂用途 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2017019767A1 (en) * | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| BR112018005322A2 (pt) * | 2015-09-18 | 2018-12-11 | Arch Oncology, Inc. | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos |
| US20190290759A1 (en) * | 2015-12-28 | 2019-09-26 | Syndax Pharmaceuticals, Inc. | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer |
| WO2017127707A1 (en) * | 2016-01-21 | 2017-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
-
2018
- 2018-10-18 PL PL18807145.0T patent/PL3697819T3/pl unknown
- 2018-10-18 CA CA3078430A patent/CA3078430A1/en active Pending
- 2018-10-18 EP EP22207465.0A patent/EP4194470A1/en active Pending
- 2018-10-18 WO PCT/US2018/056442 patent/WO2019079549A1/en not_active Ceased
- 2018-10-18 SI SI201830820T patent/SI3697819T1/sl unknown
- 2018-10-18 CN CN201880071877.6A patent/CN111315783A/zh active Pending
- 2018-10-18 KR KR1020207014146A patent/KR20200070341A/ko not_active Ceased
- 2018-10-18 EP EP18807145.0A patent/EP3697819B1/en active Active
- 2018-10-18 AU AU2018351007A patent/AU2018351007B2/en active Active
- 2018-10-18 PT PT188071450T patent/PT3697819T/pt unknown
- 2018-10-18 ES ES18807145T patent/ES2938652T3/es active Active
- 2018-10-18 JP JP2020521860A patent/JP7308190B2/ja active Active
- 2018-10-18 US US16/756,790 patent/US20210047416A1/en not_active Abandoned
-
2022
- 2022-11-22 JP JP2022186496A patent/JP7474827B2/ja active Active
-
2024
- 2024-01-12 JP JP2024003136A patent/JP2024024121A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500336A5 (https=) | ||
| KR102329584B1 (ko) | 종양 치료용 항-ｂ7-ｈ1 항체 | |
| JP2021500349A5 (https=) | ||
| JP2009539841A (ja) | 自己免疫疾患の治療における抗ｃｄ３抗体の投与 | |
| TW202529804A (zh) | 用於癌症治療的組合療法 | |
| US20260109766A1 (en) | Lag-3 antagonist therapy for melanoma | |
| US20210292415A1 (en) | Methods of treating a tumor | |
| WO2021250533A1 (en) | Methods of treatment using omalizumab or ligelizumab | |
| CN118176214A (zh) | 血液癌症的lag-3拮抗剂疗法 | |
| US20240425577A1 (en) | Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa | |
| KR20250099779A (ko) | 항-c5 항체/c5 irna 통합-제형 및 조합 요법 | |
| EP4595980A1 (en) | Method for treating membranous nephropathy with taci-fc fusion protein | |
| US20250332252A1 (en) | Antibody compositions and methods of use thereof | |
| WO2023164662A1 (en) | Treatment of squamous non small cell lung cancer | |
| WO2024099387A1 (zh) | 通过施用配体-药物偶联体治疗癌症 | |
| WO2024193675A1 (zh) | 通过施用配体-药物偶联体治疗卵巢癌 | |
| CN119630418A (zh) | 抗GARP-TGF-β1/PD-1组合疗法 | |
| JPWO2022076767A5 (https=) | ||
| CN116568307A (zh) | 用于肺癌的lag-3拮抗剂疗法 | |
| CN120456895A (zh) | 使用结合egfr的抗体与细胞毒性药物的组合的癌症治疗 | |
| CN121003695A (zh) | 抗tigit抗体和抗pd-1抗体联合治疗肿瘤 | |
| HK1224560A1 (en) | Anti-b7-h1 antibodies for treating tumors |